Turkovac

Turkovac
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesErucov-Vac
Routes of
administration		Intramuscular
Legal status
Legal status
Identifiers
CAS Number

Turkovac (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.

Clinical trials

In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.

In February 2021, Turkovac started on phase II trials with 250 participants in Turkey.

In June 2021, Turkovac started on phase III trials with 40,800 participants in Turkey. As of 2023 phase III trials continue.

Authorization

On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed. On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.

References

  1. ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ↑ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
  3. ↑ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine Erucov-Vac" at ClinicalTrials.gov
  4. ↑ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated Erucov-Vac Compared With Placebo in COVID-19 " at ClinicalTrials.gov
  5. ↑ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (Turkovac) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
  6. ↑ "ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 16 January 2024.
  7. ↑ "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.
  8. ↑ "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.